title: Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study.
abstract: This study describes the clinical, hematological, and biochemical safety of tetradecylthioacetic acid (TTA). A total of 18 healthy volunteers were included. Subjects were randomly assigned into 3 groups according to the daily given dose of TTA: group 1 (200 mg), group 2 (600 mg), and group 3 (1000 mg). TTA was given as a single oral dose for 7 consecutive days. Safety was evaluated by following the adverse events, vital signs, and hematological and biochemical parameters in blood and urine samples. Efficacy was estimated through its effects on plasma lipids profile. Few adverse events of mild severity were reported. No clinically significant changes were observed in the hematological or clinical chemical parameters in blood/urine. TTA did not induce significant changes in the blood lipids or free fatty acids, but it did result in an increase in plasma concentration of Delta9 desaturated TTA (TTA: 1n-8). Serum concentration pattern of TTA at day 1 showed a 1.5-hour lag time followed by a rapid absorption and a slower elimination phase. The median peak values were 2.9 mg/L (range, 1.1 to 5.4 mg/L), 11.5 mg/L (range, 4 to 35 mg/L), and 11 mg/L (range, 5 to 25 mg/L), in groups 1, 2, and 3, respectively (P = 0.006). The time to peak levels were 3.5 hours (range, 2.5 to 6.5 hours), 2.5 hours (range, 2.5 to 4.5 hours), and 4.5 hours (range, 2.5 to 12 hours), respectively (P = 0.2). TTA is safe and well tolerated.
authors.affiliation: Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. rpet@helse-bergen.no
authors.forename: Reidar J
authors.initials: RJ
authors.lastname: Pettersen
authors.forename: Mohamed
authors.initials: M
authors.lastname: Salem
authors.forename: Jon
authors.initials: J
authors.lastname: Skorve
authors.forename: Rune J
authors.initials: RJ
authors.lastname: Ulvik
authors.forename: Rolf K
authors.initials: RK
authors.lastname: Berge
authors.forename: Jan Erik
authors.initials: JE
authors.lastname: Nordrehaug
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000975:Antioxidants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D004573:Electrolytes / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D013440:Sulfides / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
chemical_list: D000975:Antioxidants; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004573:Electrolytes; D005230:Fatty Acids, Nonesterified; D013440:Sulfides; D014280:Triglycerides; C062078:1-(carboxymethylthio)tetradecane